Logo image of MDG1.DE

MEDIGENE AG (MDG1.DE) Stock Fundamental Analysis

FRA:MDG1 - Deutsche Boerse Ag - DE000A40ESG2 - Common Stock - Currency: EUR

1.5  -0.08 (-4.94%)

Fundamental Rating

2

MDG1 gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 69 industry peers in the Biotechnology industry. MDG1 scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. MDG1 is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MDG1 has reported negative net income.
MDG1 had a negative operating cash flow in the past year.
In the past 5 years MDG1 always reported negative net income.
MDG1 had negative operating cash flow in 4 of the past 5 years.
MDG1.DE Yearly Net Income VS EBIT VS OCF VS FCFMDG1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

1.2 Ratios

MDG1's Return On Assets of -56.15% is on the low side compared to the rest of the industry. MDG1 is outperformed by 62.32% of its industry peers.
MDG1 has a Return On Equity of -82.28%. This is comparable to the rest of the industry: MDG1 outperforms 46.38% of its industry peers.
Industry RankSector Rank
ROA -56.15%
ROE -82.28%
ROIC N/A
ROA(3y)-27.97%
ROA(5y)-28.16%
ROE(3y)-40.52%
ROE(5y)-40.06%
ROIC(3y)N/A
ROIC(5y)N/A
MDG1.DE Yearly ROA, ROE, ROICMDG1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

Looking at the Gross Margin, with a value of 72.77%, MDG1 is in the better half of the industry, outperforming 73.91% of the companies in the same industry.
In the last couple of years the Gross Margin of MDG1 has declined.
The Profit Margin and Operating Margin are not available for MDG1 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.13%
GM growth 5Y-3.96%
MDG1.DE Yearly Profit, Operating, Gross MarginsMDG1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

MDG1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MDG1 has about the same amount of shares outstanding.
Compared to 5 years ago, MDG1 has less shares outstanding
Compared to 1 year ago, MDG1 has a worse debt to assets ratio.
MDG1.DE Yearly Shares OutstandingMDG1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
MDG1.DE Yearly Total Debt VS Total AssetsMDG1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -23.75, we must say that MDG1 is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -23.75, MDG1 is not doing good in the industry: 81.16% of the companies in the same industry are doing better.
MDG1 has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.
MDG1 has a better Debt to Equity ratio (0.08) than 71.01% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -23.75
ROIC/WACCN/A
WACC7.2%
MDG1.DE Yearly LT Debt VS Equity VS FCFMDG1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 2.39 indicates that MDG1 has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.39, MDG1 is in line with its industry, outperforming 49.28% of the companies in the same industry.
A Quick Ratio of 2.39 indicates that MDG1 has no problem at all paying its short term obligations.
MDG1's Quick ratio of 2.39 is in line compared to the rest of the industry. MDG1 outperforms 56.52% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.39
MDG1.DE Yearly Current Assets VS Current LiabilitesMDG1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

MDG1 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -94.19%.
MDG1 shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -80.69%.
MDG1 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.89% yearly.
EPS 1Y (TTM)-94.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-91.4%
Revenue 1Y (TTM)-80.69%
Revenue growth 3Y-11.65%
Revenue growth 5Y-4.89%
Sales Q2Q%-6%

3.2 Future

The Earnings Per Share is expected to grow by 11.91% on average over the next years. This is quite good.
Based on estimates for the next years, MDG1 will show a very strong growth in Revenue. The Revenue will grow by 21.49% on average per year.
EPS Next Y38.46%
EPS Next 2Y20.82%
EPS Next 3Y18.2%
EPS Next 5Y11.91%
Revenue Next Year100%
Revenue Next 2Y90.69%
Revenue Next 3Y13.3%
Revenue Next 5Y21.49%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MDG1.DE Yearly Revenue VS EstimatesMDG1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M
MDG1.DE Yearly EPS VS EstimatesMDG1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MDG1 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MDG1 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDG1.DE Price Earnings VS Forward Price EarningsMDG1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDG1.DE Per share dataMDG1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as MDG1's earnings are expected to grow with 18.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.82%
EPS Next 3Y18.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDG1!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIGENE AG

FRA:MDG1 (3/26/2025, 7:00:00 PM)

1.5

-0.08 (-4.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-24 2024-10-24
Earnings (Next)03-26 2025-03-26/amc
Inst Owners2.38%
Inst Owner ChangeN/A
Ins Owners3.36%
Ins Owner ChangeN/A
Market Cap22.34M
Analysts82.5
Price Target2.96 (97.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-51.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.7
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 2.27
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-0.81
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0.41
BVpS1.32
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.15%
ROE -82.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.77%
FCFM N/A
ROA(3y)-27.97%
ROA(5y)-28.16%
ROE(3y)-40.52%
ROE(5y)-40.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.13%
GM growth 5Y-3.96%
F-Score1
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.34%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.39
Quick Ratio 2.39
Altman-Z -23.75
F-Score1
WACC7.2%
ROIC/WACCN/A
Cap/Depr(3y)17.88%
Cap/Depr(5y)24.26%
Cap/Sales(3y)5.12%
Cap/Sales(5y)6.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-94.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-91.4%
EPS Next Y38.46%
EPS Next 2Y20.82%
EPS Next 3Y18.2%
EPS Next 5Y11.91%
Revenue 1Y (TTM)-80.69%
Revenue growth 3Y-11.65%
Revenue growth 5Y-4.89%
Sales Q2Q%-6%
Revenue Next Year100%
Revenue Next 2Y90.69%
Revenue Next 3Y13.3%
Revenue Next 5Y21.49%
EBIT growth 1Y-85.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.4%
EBIT Next 3Y10.94%
EBIT Next 5Y9.18%
FCF growth 1Y-262.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-257.03%
OCF growth 3YN/A
OCF growth 5YN/A